2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T5d42,

Summary Table

Feature	Detail
Risk Factors	Women aged 45-55 (average age 51), smoking (earlier onset by ~2 years), family history of early menopause, prior bilateral oophorectomy, chemotherapy/pelvic radiation, autoimmune conditions (e.g., thyroid disease, type 1 diabetes)
Etiology	Progressive depletion of ovarian follicles leading to declining estrogen and inhibin production, with loss of negative feedback on the hypothalamic-pituitary axis
Patient Presentation	Irregular menses progressing to amenorrhea, vasomotor symptoms (hot flashes, night sweats), sleep disturbance, mood changes, vaginal dryness, dyspareunia
Classic Physical Exam	Vaginal mucosal atrophy (pale, thin, dry epithelium), decreased vaginal rugae, possible uterine/cervical atrophy on bimanual exam
Key Diagnostic Results	Elevated FSH > 30 mIU/mL on two occasions, low estradiol (< 30 pg/mL); diagnosis is clinical in women > 45 with 12 months of amenorrhea
Management	Hormone replacement therapy (HRT) for symptomatic relief in appropriate candidates; vaginal estrogen for isolated genitourinary symptoms; SSRIs/SNRIs or gabapentin as non-hormonal alternatives
Keywords	"12 months of amenorrhea," "hot flashes and night sweats," "elevated FSH," "vaginal atrophy," "vasomotor symptoms"

1. Pathophysiology

Menopause represents the permanent cessation of menstruation resulting from irreversible loss of ovarian follicular activity. Throughout a woman's reproductive life, the finite pool of primordial follicles undergoes continuous atresia. By the late 40s, the remaining follicle count drops below the threshold required to sustain regular ovulatory cycles.

As follicles decline, estradiol and inhibin B production fall. Since inhibin B is the primary negative feedback signal to FSH secretion from the anterior pituitary, its loss results in a compensatory and progressive rise in FSH. This is why FSH becomes the hallmark laboratory finding. The elevated FSH initially drives the remaining follicles into accelerated, irregular recruitment, which explains the erratic menstrual cycles seen during the perimenopause transition (cycles may shorten, then lengthen, then become anovulatory).

Once follicular reserves are fully exhausted, estradiol levels become chronically low. This estrogen withdrawal is directly responsible for the classic symptom profile:

Vasomotor symptoms (hot flashes, night sweats) arise because estrogen modulates the thermoregulatory center in the hypothalamus. Low estrogen narrows the thermoneutral zone, meaning even minor core temperature fluctuations trigger inappropriate heat-dissipation responses (peripheral vasodilation, sweating). This is the most commonly tested symptom.

Genitourinary syndrome of menopause (previously called vulvovaginal atrophy) occurs because the vaginal epithelium, urethra, and bladder trigone are estrogen-dependent tissues. Without estrogen, the vaginal mucosa thins, loses glycogen, and the pH rises (becoming more alkaline), predisposing to recurrent UTIs and dyspareunia. Unlike vasomotor symptoms, genitourinary symptoms do not improve with time and tend to worsen progressively.

Bone loss accelerates because estrogen normally suppresses osteoclast activity. The first 5-7 years after menopause see the most rapid decline in bone mineral density, placing postmenopausal women at elevated risk for osteoporosis and fracture.

The cardiovascular risk profile also shifts: estrogen has favorable effects on lipid metabolism (raising HDL, lowering LDL) and endothelial function. After menopause, LDL rises and HDL falls, contributing to the increased incidence of coronary artery disease in postmenopausal women.

2. Classification and Clinical Manifestation

Stage	Definition	Menstrual Pattern	Key Features
Early Perimenopause	Onset of menstrual irregularity	Variable cycle length (> 7 days different from baseline)	Vasomotor symptoms may begin; FSH may be normal or mildly elevated
Late Perimenopause	Progressive ovarian failure	Amenorrhea intervals of 60 days or more	Vasomotor symptoms peak; FSH consistently elevated
Menopause	12 consecutive months of amenorrhea (retrospective diagnosis)	No menses	FSH > 30 mIU/mL; low estradiol
Postmenopause	All years following final menstrual period	Absent	Genitourinary atrophy progresses; osteoporosis risk increases
Premature Ovarian Insufficiency	Menopause occurring before age 40	Oligomenorrhea or amenorrhea	Requires karyotype, FMR1 premutation testing, and adrenal/thyroid antibody screening
Early Menopause	Menopause occurring between ages 40-45	Progressive amenorrhea	Intermediate risk category; warrants investigation for secondary causes

Clinical Manifestation

Domain	Manifestations	Timeline
Vasomotor	Hot flashes, night sweats, sleep disruption, palpitations	Peaks in late perimenopause; median duration 7.4 years
Genitourinary	Vaginal dryness, dyspareunia, urinary urgency/frequency, recurrent UTIs	Progressive and chronic; worsens without treatment
Neuropsychiatric	Mood lability, irritability, difficulty concentrating, depressive symptoms	Most prominent during the menopausal transition
Musculoskeletal	Joint stiffness, arthralgia, accelerated bone loss	Bone loss most rapid in first 5-7 postmenopausal years
Metabolic	Central adiposity, insulin resistance, dyslipidemia (increased LDL, decreased HDL)	Gradual, cumulative

3. Diagnostic Workup

Test	Role	Expected Finding
Clinical history	Best initial "test"	12 months of amenorrhea in a woman > 45 years old
Serum FSH	Confirmatory when diagnosis is uncertain	> 30 mIU/mL on two measurements 4-6 weeks apart
Serum estradiol	Supportive	< 30 pg/mL
TSH	Rule out thyroid disease	Normal (excludes hypothyroidism mimicking menopausal symptoms)
Pregnancy test (beta-hCG)	Mandatory in perimenopausal women with amenorrhea	Negative
DEXA scan	Osteoporosis screening	Recommended at age 65 (or earlier if risk factors present)
Endometrial biopsy / Transvaginal ultrasound	Evaluate abnormal uterine bleeding	Required if bleeding pattern is concerning (e.g., heavy/prolonged bleeding, any postmenopausal bleeding)

In women older than 45 with classic symptoms and 12 months of amenorrhea, the diagnosis of menopause is entirely clinical. No laboratory testing is required. This is a frequently tested point: the exam will present a straightforward clinical picture and test whether you order unnecessary labs.

FSH measurement becomes the best initial test when the clinical picture is ambiguous. This includes women aged 40-45 with irregular cycles, women who have undergone hysterectomy (no menstrual history to reference), or women on hormonal contraception that masks menstrual patterns. A single elevated FSH can be misleading during perimenopause because levels fluctuate widely, so two measurements separated by 4-6 weeks are recommended to confirm.

TSH and beta-hCG are important rule-out tests. Hypothyroidism can mimic several menopausal symptoms (fatigue, menstrual irregularity, mood changes, weight gain), and pregnancy must always be excluded in any woman of reproductive potential presenting with amenorrhea, even if she is in her late 40s.

Anti-Mullerian hormone (AMH) reflects ovarian reserve and declines to undetectable levels at menopause. While increasingly used in fertility assessment, it is not routinely tested for menopause diagnosis. It is more relevant in evaluating premature ovarian insufficiency.

For premature ovarian insufficiency (menopause before 40), the workup is more extensive: karyotype (to detect Turner syndrome mosaicism such as 45,X), FMR1 premutation testing (fragile X carrier status), 21-hydroxylase antibodies (autoimmune adrenal insufficiency), and thyroid peroxidase antibodies should all be obtained.

A critical exam scenario: any postmenopausal bleeding requires endometrial evaluation regardless of how long the patient has been menopausal. The standard approach is transvaginal ultrasound first. If endometrial thickness is > 4 mm, endometrial biopsy follows. The concern is endometrial hyperplasia or carcinoma.

4. Management and Treatment

Clinical Scenario	Treatment	Key Details
Vasomotor symptoms (with uterus)	Combined estrogen + progestogen	Conjugated equine estrogen 0.625 mg/day or estradiol 1 mg/day PO + medroxyprogesterone acetate 2.5 mg/day continuous, or micronized progesterone 100-200 mg/day for 12-14 days/month
Vasomotor symptoms (without uterus)	Estrogen alone	Conjugated equine estrogen 0.625 mg/day or estradiol 1 mg/day PO; no progestogen needed
Isolated genitourinary symptoms	Low-dose vaginal estrogen	Estradiol vaginal cream, estradiol ring (Estring), or estradiol vaginal tablet; does not require systemic progestogen
Contraindication to HRT	Non-hormonal alternatives	Paroxetine 7.5 mg/day (only FDA-approved non-hormonal option for hot flashes), venlafaxine 37.5-75 mg/day, gabapentin 300 mg TID
Fezolinetant	Neurokinin 3 receptor antagonist	45 mg PO daily; newer non-hormonal option approved for vasomotor symptoms
Osteoporosis prevention	Calcium, vitamin D, weight-bearing exercise	Calcium 1200 mg/day + vitamin D 800-1000 IU/day; bisphosphonates if DEXA confirms osteoporosis
Premature ovarian insufficiency	HRT until natural menopause age (~51)	Essential for bone, cardiovascular, and cognitive protection

Hormone replacement therapy (HRT) remains the most effective treatment for vasomotor symptoms. The fundamental principle for exam purposes: a woman with an intact uterus must receive a progestogen alongside estrogen to prevent unopposed estrogen stimulation of the endometrium, which leads to endometrial hyperplasia and increases the risk of endometrial carcinoma. A woman who has had a hysterectomy can safely receive estrogen-only therapy.

The recommended approach is to use the lowest effective dose for the shortest necessary duration. Current guidelines support initiating HRT in symptomatic women within 10 years of menopause onset or before age 60 (the "window of opportunity"). In this group, the benefits of symptom relief and bone protection outweigh the risks. Starting HRT in women over 60 or more than 10 years past menopause is associated with increased cardiovascular and thromboembolic risk and is generally not recommended.

Absolute contraindications to systemic HRT include: unexplained vaginal bleeding, active or recent breast cancer, active thromboembolic disease or history of DVT/PE, active liver disease, and known thrombophilia (e.g., Factor V Leiden). Coronary heart disease is also a contraindication to initiating HRT.

Transdermal estrogen (patches, gels) is preferred over oral formulations in women with elevated thrombotic risk, hypertriglyceridemia, or migraine with aura, because transdermal delivery bypasses hepatic first-pass metabolism and does not increase clotting factor production or triglyceride levels.

For isolated genitourinary symptoms (vaginal dryness, dyspareunia, recurrent UTIs without bothersome hot flashes), low-dose vaginal estrogen is the treatment of choice. Systemic absorption is minimal, and current evidence does not support the need for concomitant progestogen. This is a commonly tested distinction.

Non-hormonal alternatives are indicated when HRT is contraindicated or refused. Paroxetine 7.5 mg/day (low-dose, brand name Brisdelle) is the only FDA-approved non-hormonal medication for hot flashes. Venlafaxine and gabapentin are also effective. Paroxetine should be avoided in women taking tamoxifen because it inhibits CYP2D6, the enzyme required to convert tamoxifen to its active metabolite endoxifen.

For premature ovarian insufficiency, HRT is not optional but rather strongly recommended until at least the age of natural menopause (approximately 51 years) to mitigate the long-term consequences of prolonged estrogen deficiency: accelerated osteoporosis, increased cardiovascular mortality, and possible cognitive decline.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Is Similar	Key Discriminator
Hypothyroidism	Fatigue, weight gain, menstrual irregularity, mood changes, cold intolerance	TSH is elevated; no vasomotor symptoms (hot flashes); cold intolerance rather than heat intolerance
Pregnancy	Amenorrhea in a perimenopausal woman	Positive beta-hCG; breast tenderness and nausea more prominent; FSH is suppressed, not elevated
Hyperprolactinemia	Amenorrhea, decreased libido	Elevated prolactin; may have galactorrhea and visual field defects (pituitary adenoma); FSH is low/normal, not elevated
Premature ovarian insufficiency	Identical symptoms to menopause	Age < 40 years; requires additional workup (karyotype, FMR1, autoimmune antibodies)
Functional hypothalamic amenorrhea	Amenorrhea in a younger woman with low estrogen	History of excessive exercise, caloric restriction, or psychological stress; low FSH and low LH (hypogonadotropic hypogonadism) rather than elevated FSH
Polycystic ovary syndrome (PCOS)	Irregular menses, mood changes	Hyperandrogenism (acne, hirsutism), elevated LH:FSH ratio (not isolated FSH elevation), typically in younger patients
Carcinoid syndrome	Flushing episodes	Flushing is persistent and associated with diarrhea and wheezing; elevated 5-HIAA in 24-hour urine
Pheochromocytoma	Episodes of sweating and palpitations	Paroxysmal hypertension, headache, diaphoresis; elevated plasma metanephrines

6. Traps and High-Yield Pearls

The most common way students lose points on menopause questions involves ordering unnecessary labs in a straightforward clinical scenario. When a 52-year-old woman presents with 12 months of amenorrhea and classic vasomotor symptoms, the answer is a clinical diagnosis. Choosing "check FSH" when no ambiguity exists is a trap.

The second major pitfall is forgetting to add progestogen in a woman with an intact uterus receiving estrogen therapy. Test-writers will present a patient on estrogen-only HRT who then develops abnormal uterine bleeding. The teaching point is unopposed estrogen and endometrial hyperplasia risk.

A third commonly tested concept: the exam presents a breast cancer survivor with debilitating hot flashes and asks for the next best step. HRT is contraindicated. The correct answer is a non-hormonal agent (paroxetine, venlafaxine, or gabapentin). However, if this patient is also taking tamoxifen, paroxetine is wrong due to CYP2D6 inhibition. Venlafaxine or gabapentin becomes the answer.

Watch for the vignette describing a postmenopausal woman with any vaginal bleeding, even spotting. This always demands endometrial evaluation (transvaginal ultrasound followed by biopsy if indicated). "Reassurance" or "observation" is never acceptable for postmenopausal bleeding.

Finally, premature ovarian insufficiency (before age 40) is treated differently from natural menopause: HRT is strongly indicated until the average age of natural menopause to prevent long-term sequelae. A young woman presenting with elevated FSH and amenorrhea should not simply be told she is "going through menopause early" without a thorough etiologic workup and initiation of hormone therapy.

The core competency being tested across menopause questions is the ability to match clinical context to the correct diagnostic and management pathway: clinical diagnosis when the picture is clear, targeted labs when it is not, appropriate HRT selection based on uterine status and contraindications, and recognition of red flags that demand further investigation.

1e:["$","$L2d",null,{"article":{"id":"a49969b9-d639-4366-8f91-36706e2318a7","title":"Menopause","content":"$2e","category":"Reproduksi","created_at":"2026-05-16T17:04:24.028356+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]